IRIS
NECCHI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.542
AS - Asia 7.418
NA - Nord America 5.732
SA - Sud America 2.228
Continente sconosciuto - Info sul continente non disponibili 471
AF - Africa 171
OC - Oceania 15
Totale 23.577
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.366
RU - Federazione Russa 4.298
SG - Singapore 2.682
CN - Cina 2.011
BR - Brasile 1.815
HK - Hong Kong 1.121
SE - Svezia 917
VN - Vietnam 713
IT - Italia 681
DE - Germania 361
FR - Francia 352
BD - Bangladesh 300
RO - Romania 267
CA - Canada 164
IN - India 160
AR - Argentina 157
GB - Regno Unito 135
FI - Finlandia 121
AT - Austria 109
MX - Messico 95
ID - Indonesia 66
PL - Polonia 63
IQ - Iraq 61
EC - Ecuador 59
NL - Olanda 58
ZA - Sudafrica 58
JP - Giappone 55
ES - Italia 47
CO - Colombia 46
TR - Turchia 38
IE - Irlanda 36
VE - Venezuela 35
PY - Paraguay 33
CL - Cile 31
PK - Pakistan 25
UA - Ucraina 25
MA - Marocco 22
TN - Tunisia 22
MY - Malesia 21
PE - Perù 21
UY - Uruguay 19
JM - Giamaica 18
NP - Nepal 18
UZ - Uzbekistan 17
EG - Egitto 15
SA - Arabia Saudita 15
KE - Kenya 14
AU - Australia 13
LT - Lituania 13
CR - Costa Rica 12
NI - Nicaragua 12
PT - Portogallo 11
AZ - Azerbaigian 10
DO - Repubblica Dominicana 10
IR - Iran 10
JO - Giordania 10
PH - Filippine 10
AE - Emirati Arabi Uniti 9
BB - Barbados 9
DZ - Algeria 9
GT - Guatemala 9
EU - Europa 8
SN - Senegal 8
TT - Trinidad e Tobago 8
BO - Bolivia 7
LB - Libano 7
NG - Nigeria 7
BE - Belgio 6
BH - Bahrain 6
HN - Honduras 6
KR - Corea 6
KW - Kuwait 6
KZ - Kazakistan 6
PA - Panama 6
PR - Porto Rico 6
TH - Thailandia 6
AL - Albania 5
BG - Bulgaria 5
IL - Israele 5
MD - Moldavia 5
CI - Costa d'Avorio 4
GR - Grecia 4
KH - Cambogia 4
OM - Oman 4
SV - El Salvador 4
BA - Bosnia-Erzegovina 3
BN - Brunei Darussalam 3
CZ - Repubblica Ceca 3
ET - Etiopia 3
GY - Guiana 3
HU - Ungheria 3
KG - Kirghizistan 3
LY - Libia 3
SK - Slovacchia (Repubblica Slovacca) 3
AO - Angola 2
BY - Bielorussia 2
CH - Svizzera 2
CW - ???statistics.table.value.countryCode.CW??? 2
CY - Cipro 2
GE - Georgia 2
Totale 23.088
Salva come PNG Salva come JPEG
Città #
Singapore 1.241
Hong Kong 1.110
Moscow 950
Ashburn 669
Dallas 579
San Jose 508
Council Bluffs 436
Shanghai 428
Hefei 345
Lawrence 302
Princeton 302
Ho Chi Minh City 293
Lauterbourg 288
Beijing 269
New York 252
São Paulo 165
Milan 156
Hanoi 153
Los Angeles 153
Santa Clara 148
Nuremberg 113
Boardman 96
Rome 87
Helsinki 70
Rio de Janeiro 68
Munich 61
Orem 53
Montreal 49
Brooklyn 45
Warsaw 45
Tokyo 43
Vienna 41
Phoenix 39
Belo Horizonte 37
Brasília 36
Da Nang 36
Frankfurt am Main 36
Turku 36
Dublin 35
Mexico City 34
Atlanta 33
Denver 33
Toronto 33
Chennai 31
Haiphong 31
Chicago 30
Houston 30
Guangzhou 29
Mumbai 28
Poplar 26
Porto Alegre 26
Buffalo 25
Johannesburg 25
Turin 25
Campinas 23
London 23
Salvador 23
Pune 22
Seattle 22
Bar Harbor 21
Amsterdam 20
Curitiba 20
Stockholm 20
Biên Hòa 18
Omaha 18
Washington 18
Caxias do Sul 17
Columbus 17
Erbil 17
Guayaquil 17
Manchester 17
Bogotá 16
Recife 16
Tashkent 16
Baghdad 15
Dhaka 15
Hangzhou 15
Hải Dương 15
Las Vegas 15
Montevideo 15
Sorocaba 15
Tianjin 15
Charlotte 14
Fortaleza 14
Kassel 14
Lappeenranta 14
Manaus 14
Naples 14
Quito 14
Ankara 13
Buenos Aires 13
Guarulhos 13
Nairobi 13
Ribeirão Preto 13
San Francisco 13
The Dalles 13
Asunción 12
Boston 12
Goiânia 12
Lima 12
Totale 10.950
Salva come PNG Salva come JPEG
Nome #
Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors 395
[18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab 236
A comprehensive assessment of frailty status on surgical, functional and oncologic outcomes in patients treated with partial nephrectomy––A large, retrospective, single-center study 173
A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02 163
Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy 159
Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard 152
Androgen annihilation versus advanced androgen blockage as first line treatment for metastatic castration resistant prostate cancer: A systematic review and meta-analysis 148
Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review 143
Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis 142
A global approach to improving penile cancer care 141
Neglected lymph nodal metastases in patients with renal cancer: when to extend the anatomical template of lymph node dissection during nephrectomy 137
Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study 136
Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer 135
Preoperative risk calculator for the probability of completing nephron sparing for kidney cancer 134
Accuracy of Transurethral Resection of the Bladder in Detecting Variant Histology of Bladder Cancer Compared with Radical Cystectomy 134
A Combination of Cisplatin and 5-Fluorouracil With a Taxane in Patients Who Underwent Lymph Node Dissection for Nodal Metastases From Squamous Cell Carcinoma of the Penis: Treatment Outcome and Survival Analyses in Neoadjuvant and Adjuvant Settings 133
Pembrolizumab in advanced renal cell carcinoma: a meta-analysis providing level 1a evidence 127
Use of 18F-fluoro-2-deoxy-d-glucose (18F-FDG) PET/CT for lymph node assessment before radical cystectomy in bladder cancer patients 127
Clinical, pathological and long-term oncologic outcomes of papillary type I vs. type II renal cell carcinoma 126
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation 126
Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Cancer 125
Pulmonary lesion after surgery for renal cancer: progression or new primary? 124
Upper Tract Urothelial Carcinoma in the Lynch Syndrome Tumour Spectrum: A Comprehensive Overview from the European Association of Urology - Young Academic Urologists and the Global Society of Rare Genitourinary Tumors 124
Long-term functional outcomes in patients undergoing radical nephrectomy for renal cell carcinoma and tumor thrombus 123
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial 123
How to optimize the use of adjuvant pembrolizumab in renal cell carcinoma: which patients benefit the most? 122
Association Between Human Papillomavirus Infection and Outcome of Perioperative Nodal Radiotherapy for Penile Carcinoma 122
Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study☆ 120
Head-to-head comparison of all the prognostic models recommended by the European Association of Urology Guidelines to predict oncologic outcomes in patients with renal cell carcinoma 119
Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration 119
A risk calculator predicting recurrence in lymph node metastatic penile cancer 118
Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up 117
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma 113
Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study) 113
Causal contributors to tissue stiffness and clinical relevance in urology 113
Immunotherapy in advanced kidney cancer: an alternative meta-analytic method using reconstructed survival data in case of proportional hazard assumption violation 112
Re: Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-Invasive Bladder Carcinoma with Variant Histologies 112
ASSOCIATION BETWEEN BRCA 1/2 POLYMORPHISMS AND DISEASE AGGRESSIVENESS IN A PROSPECTIVE COHORT OF PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY 112
PF-03446962, a fully-human monoclonal antibody against transforming growth-factor beta (TGF beta) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial 110
Contemporary Treatment Patterns and Outcomes for Patients with Penile Squamous Cell Carcinoma: Identifying Management Gaps to Promote Multi-institutional Collaboration 110
Von Hippel-Lindau disease-associated renal cell carcinoma: a call to action 109
Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy 109
Adjuvant chemotherapy is ineffective in patients with bladder cancer and variant histology treated with radical cystectomy with curative intent 107
Cabozantinib Plus Durvalumab in Patients With Advanced Urothelial Carcinoma After Platinum Chemotherapy: Safety and Preliminary Activity of the Open-Label, Single-Arm, Phase 2 ARCADIA Trial 107
Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis 105
Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study 104
Bladder-sparing combination treatments for muscle-invasive bladder cancer: A plea for standardized assessment and definition of clinical trials endpoints 103
Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial 102
An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer 102
ASSOCIATION BETWEEN POLYMORPHISMS OF HOMOLOGOUS RECOMBINATION RAD51B AND DISEASE RECURRENCE IN A PROSPECTIVE COHORT OF PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY 101
Advanced Squamous Cell Carcinomas of the Pelvic and Perineal Region: A Comprehensive Genomic Profiling Study 101
[The treatment of early-stage germ cell tumors of the testis (GCTT)]. [Il trattamento dei Tumori Germinali del Testicolo (TGT) in fase iniziale.] 101
Neoadjuvant and adjuvant immunotherapy in renal cell carcinoma 101
Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab? 100
Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies 99
Re: Siamak Daneshmand, Azadeh Nazemi. Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer: Current Evidence. Eur Urol Focus 2020;6:639–41 98
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial 97
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial 96
Multidisciplinary management of patients diagnosed with von Hippel-Lindau disease: A practical review of the literature for clinicians 95
High-risk Surgically Resected Renal Cell Carcinoma: Is There a Role for Adjuvant VEGF-TKI Inhibitors? 95
The obesity paradox in metastatic castration-resistant prostate cancer 94
Topographic modification of the extracellular matrix precedes the onset of bladder cancer 91
Adjuvant Systemic Therapy for High-risk Muscle-invasive Bladder Cancer After Radical Cystectomy: Current Options and Future Opportunities 91
Evaluation of cognitive function in trials testing new-generation hormonal therapy in patients with prostate cancer: A systematic review 90
A Plea for Economically Sustainable Evidence-based Guidelines 90
Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer 89
Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection Following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial 88
Intermediate- and high-risk nonmuscle invasive bladder cancer: Where do we stand? 88
The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3) 87
Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty 87
Immunohistochemistry to Enhance Prognostic Allocation and Guide Decision-Making of Patients With Advanced Urothelial Cancer Receiving First-Line Chemotherapy 87
Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study 87
Survival Outcomes After Immediate Radical Cystectomy Versus Conservative Management with Bacillus Calmette-Guérin Among T1 High-grade Micropapillary Bladder Cancer Patients: Results from a Multicentre Collaboration 87
FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression 86
A Suggested Prognostic Reclassification of Intermediate and Poor-Risk Nonseminomatous Germ Cell Tumors 86
Risk factors and survival outcomes for upstaging after inguinal lymph node dissection for cN1 penile squamous cell carcinoma 85
Adjuvant Therapy in Nonmetastatic High-risk Kidney Cancer: Importance of the Timing of Postnephrectomy Imaging and Treatment Delivery 85
Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral Center 85
Neoadjuvant versus adjuvant chemotherapy for upper tract urothelial carcinoma 82
Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology–Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration 81
A Prognostic Model Including Pre- and Postsurgical Variables to Enhance Risk Stratification of Primary Mediastinal Nonseminomatous Germ Cell Tumors: The 27-Year Experience of a Referral Center 80
Prediction of the Need for an Extended Lymphadenectomy at the Time of Radical Cystectomy in Patients with Bladder Cancer 80
Sex-specific Alterations in the Urinary and Tissue Microbiome in Therapy-naïve Urothelial Bladder Cancer Patients 80
Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy Failure 77
Penile cancer 77
Administration of high-dose chemotherapy with stem cell support in patients 40 years of age or older with advanced germ cell tumours: a retrospective study from the European Society for Blood and Marrow Transplantation database 77
An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis 76
A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy? 76
Conventional-Dose Versus High-Dose Chemotherapy As First Salvage Treatment in Male Patients With Metastatic Germ Cell Tumors: Evidence From a Large International Database 75
Penile cancer 75
Immune-based therapies in penile cancer 74
Multicenter Validation of Histopathologic Tumor Regression Grade After Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma 73
Neoadjuvant chemotherapy for lymph node-positive penile cancer: Current evidence and knowledge 72
Revolutionizing care for rare genitourinary tumours 72
Reliability of Serum Tumor Marker Measurement to Diagnose Recurrence in Patients with Clinical Stage I Nonseminomatous Germ Cell Tumors Undergoing Active Surveillance: A Systematic Review 72
Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ cell tumors: long-term efficacy and safety outcomes(dagger) 71
Identifying an optimal lymph node yield for penile squamous cell carcinoma: prognostic impact of surgical dissection 71
Neoadjuvant Chemotherapy VI-RADS Scores for Assessing Muscle-invasive Bladder Cancer Response to Neoadjuvant Immunotherapy with Multiparametric MRI 70
The role of 18F-FAZA PET/CT in detecting lymph node metastases in renal cell carcinoma patients: a prospective pilot trial 70
Teratoma With Somatic-Type Malignant Components in Germ Cell Tumors of the Testis: A Clinicopathologic Analysis of 40 Cases With Outcome Correlation 70
Totale 10.784
Salva come PNG Salva come JPEG
Categoria #
all - tutte 152.168
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 152.168
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022270 0 53 3 101 1 8 13 10 13 11 4 53
2022/20231.668 675 354 123 38 18 233 47 94 48 5 15 18
2023/2024934 23 57 65 63 79 182 132 118 7 20 44 144
2024/20254.910 602 94 75 78 84 350 861 490 861 739 292 384
2025/202614.085 1.026 1.134 972 1.997 967 367 1.063 944 3.794 728 534 559
2026/20271.457 658 799 0 0 0 0 0 0 0 0 0 0
Totale 23.577